CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL).

被引：0
|
作者：
Rawstron, AC
Davies, FE
Evans, P
Morgan, GJ
Jamil, A
Galvin, MC
Haynes, AP
Hale, G
Hillmen, P
机构：
[1] UNIV LEEDS,GEN INFIRM,DEPT HAEMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND
[2] PINDERFIELDS GEN HOSP,WAKEFIELD,ENGLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2356 / 2356
页数：1
相关论文
共 50 条
  • [31] Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?
    Yang, Shenmiao
    Gale, Robert Peter
    Shi, Hongxia
    Liu, Yanrong
    Lai, Yueyun
    Lu, Jin
    Huang, Xiaojun
    LEUKEMIA RESEARCH, 2018, 73 : 16 - 20
  • [32] Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)
    Zent, Clive S.
    Kay, Neil E.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (01) : 47 - 59
  • [33] Campath-1-h therapy of patients with advanced B-cell chronic lymphocytic leukemia.
    Mahe, B
    Gueglio, B
    Morineau, N
    Vigier, M
    Moreau, P
    Chevallier, P
    Milpied, NJ
    Harousseau, JL
    BLOOD, 2002, 100 (11) : 361B - 361B
  • [34] Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL)
    Bloor, Adrian
    De Cock, Erwin
    Hatswell, Anthony J.
    Wasiak, Radek
    Elvidge, Jamie
    Stapelkamp, Ceilidh
    Hadjivassileva, Tsveta
    Haiderali, Amin
    Delgado, Julio
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (03) : 449 - 452
  • [35] The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
    Eyre, Toby A.
    Roeker, Lindsey E.
    Fox, Christopher P.
    Gohill, Satyen H.
    Walewska, Renata
    Walter, Harriet S.
    Forconi, Francesco
    Broom, Angus
    Arumainathan, Arvind
    Brander, Danielle M.
    Allan, John N.
    Schuster, Stephen J.
    Hill, Brian T.
    Lansigan, Frederick
    Cheson, Bruce D.
    Lamanna, Nicole
    Coombs, Catherine C.
    Barr, Paul M.
    Skarbnik, Alan P.
    Shadman, Mazyar
    Ujjani, Chaitra S.
    Pearson, Laurie
    Pagel, John M.
    Jacobs, Ryan
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 918 - 923
  • [36] Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
    Kuss, Bryone J.
    Tam, Constantine S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 5 - 10
  • [37] Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection
    Heider, U
    Fleissner, C
    Zavrski, I
    Jakob, C
    Dietzel, T
    Eucker, J
    Ockenga, J
    Possinger, K
    Sezer, O
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (01) : 64 - 66
  • [38] Maintenance therapy with a monthly injection of Campath-1H in refractory chronic leukemia and NHL patients.
    Thieblemont, C
    Bouafia, F
    Hornez, E
    Hequet, O
    Arnaud, P
    Espinouse, D
    Salles, G
    Coiffier, B
    BLOOD, 2002, 100 (11) : 805A - 805A
  • [39] Eradication of detectable minimal disease with Campath-1H therapy results in prolonged survival in patients with refractory B-CLL.
    Kennedy, B
    Rawstron, A
    Haynes, A
    Fegan, C
    Leach, M
    Tighe, J
    Rassam, S
    Hale, G
    Morgan, G
    Hillmen, P
    BLOOD, 2001, 98 (11) : 367A - 367A
  • [40] Feasiblity of autologous stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine and Campath-1H.
    Tedeschi, A
    Cairoli, R
    Montillo, M
    Marenco, P
    Grillo, G
    Rossi, V
    Cafro, AM
    Intropido, L
    Morra, E
    BLOOD, 2004, 104 (11) : 520A - 520A
12345